Your session is about to expire
← Back to Search
Atezolizumab + Bevacizumab Before Surgery for Liver Cancer
Study Summary
This trial is testing a combination of immunotherapy and bevacizumab before surgery in treating patients with resectable liver cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have experienced severe allergic reactions to certain types of medications called chimeric or humanized antibodies.I have some limitations in physical activity but can walk and take care of myself.I have a serious heart condition, such as heart failure or unstable angina.I have been treated for cancer, have another active cancer, or had cancer in the last 2 years.My liver cancer diagnosis is confirmed by tests or clinical criteria.You have a history of an autoimmune disease or a weakened immune system.I can provide a tumor sample or am willing to have a biopsy for research.I have not used high dose steroids, vaccines, antibiotics, immunostimulatory agents, anticoagulants (except aspirin), or total parenteral nutrition within the specified time frames before starting the study treatment.I have hepatitis with controlled HBV levels and am on or willing to start treatment.I have had an esophagus check for varices within the last 6 months.I have a history of blood clots, bleeding disorders, or significant blood vessel diseases.I have had a severe infection in the last 4 weeks.I have had bleeding from untreated varices in my esophagus or stomach.I have coughed up blood in the last 30 days.I have had issues like a fistula or abscess in my abdomen within the last 6 months.I have a cancer lesion that is at least 10 mm large, confirmed by imaging.My urine protein levels are low, under 2+ if tested with a dipstick.I have a serious lung condition like TB or pneumonia.I am not breastfeeding.I need regular procedures to remove fluid build-up in my body.My blood pressure is high (150/100 mmHg or more).My cancer is a specific type of liver cancer.I had surgery less than 6 weeks ago.You are allergic to bevacizumab.My liver function is classified as very good.I am 18 years old or older.I have had a stem cell, liver, or other organ transplant.My organs and bone marrow are functioning well.My cancer is operable and hasn't spread beyond the liver.I have a history of brain or spinal cord disease.You have other serious health conditions that would make it unsafe for you to receive the experimental treatment.You are allergic to atezolizumab or any of its ingredients.
- Group 1: Treatment (atezolizumab, bevacizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does using Atezolizumab pose any substantial risks to users?
"Due to the fact that this is a Phase 2 trial, with safety data present but efficacy yet to be confirmed, our team at Power assigned Atezolizumab a score of 2."
What medical afflictions can be aided by the administration of Atezolizumab?
"Atezolizumab has been successfully utilised to treat non-small cell lung carcinoma, as well as recurrent platinum-sensitive epithelial ovarian cancer and postoperative recurrent cases of the same."
Are there still opportunities available for people to take part in this experiment?
"Affirmative. According to clinicaltrials.gov, this study is actively enrolling patients with a posted date of February 10th 2021 and last edited on October 12th 2022. They are seeking 30 participants from two sites in total."
How many people have been invited to take part in this trial?
"Affirmative. According to clinicaltrials.gov, enrollment is open for this research project which was first announced on February 10th 2021 and most recently revised on October 12th 2022. The trial requires 30 individuals across two sites."
Are there any precedential studies related to Atezolizumab?
"Currently, 621 clinical trials are researching the efficacy of Atezolizumab. Of those, 142 trials have advanced to Phase 3 and they span 31793 locations worldwide with many based in Taibei, Taiwan."
What are the primary aims of this medical investigation?
"This trial, which will be assessed up to two years after treatment has concluded, aims to monitor the frequency of adverse reactions. Secondary goals include observing overall survival with Kaplan-Meier methods and utilizing log-rank tests to determine a link between this metric and complete response or partial response based on RECIST 1.1/mRECIST1.0 criteria. Additionally, duration of response will also be estimated using Kaplan-Meier techniques"
Share this study with friends
Copy Link
Messenger